ArticleBMC cardiovascular disorders2026
Association between asymmetric dimethylarginine level and central obesity among patients with acute myocardial infarction: exploratory cross-sectional study.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAsymmetric dimethylarginine (ADMA), a competitive inhibitor of endothelial nitric oxide synthase (eNOS), has been implicated in atherosclerotic cardiovascular disease. However, the prognostic significance of baseline ADMA in the context of central obesity among patients with acute myocardial infarction (AMI) remains insufficiently characterized.
objectivesThis study aimed to investigate whether central obesity (CO) is associated with elevated ADMA levels among patients with AMI in the Gaza Strip, Palestine.
methodsA comparative cross-sectional study was conducted at four governmental hospitals in the Gaza Strip. One hundred and twenty patients with a confirmed diagnosis of AMI aged 30-65 years were recruited via convenience sampling between January 2023 and October 2023. Anthropometric parameters, including Body Mass Index (BMI) and Waist Circumference (WC), biochemical measurements such as ADMA, homocysteine (Hcy), and lipid profile, and lifestyle factors were assessed. Group differences were evaluated using independent-samples t-tests. Pearson correlations and Multiple linear regression were employed to explore inter-variable relationships.
resultsOf 120 AMI patients, 102 (85.0%) were male, and 18 (15.0%) were female (mean age 53.49 ± 7.35 years). Central obesity (WC >102 cm in men; >88 cm in women) was present in 53.3% of participants. Statistically significant differences between the centrally obese and non-obese groups were observed for total cholesterol (P = 0.030), triglycerides (P = 0.048), and HDL-c (P = 0.043). ADMA and Hcy levels were significantly higher in the centrally obese group than in the non-obese group (differences: 35.1 ng/mL and 7.7 µmol/L, respectively; P = 0.040 and P = 0.009). Multiple Linear Regression identified WC as the only significant independent predictor of ADMA (β = 1.22, 95% CI 0.003- 2.445, P = 0.049).
conclusionsWC was significantly associated with elevated ADMA levels in patients with AMI. Given the cross-sectional design, these findings should be regarded as preliminary, and further longitudinal studies are needed to confirm whether central obesity contributes to elevated ADMA and cardiovascular risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.